Advertisement
Advertisement
EVGN
EVOGENE LTD.
0.63
USDSponsored
+0.03
+5.37%
Aug 10, 15:59 UTC -4
Closed
After-Market
0.63
0.00
-0.52%
EVGN Earnings Reports
Positive Surprise Ratio
EVGN beat 15 of 31 last estimates.
48%
Next Report
Date of Next Report
Aug 18, 2026
Estimate for Q2 26 (Revenue/ EPS)
$331.50K
/-$0.27
Implied change from Q1 26 (Revenue/ EPS)
-0.75%
/-55.00%
Implied change from Q2 25 (Revenue/ EPS)
-62.50%
/-56.45%
EVOGENE LTD. earnings per share and revenue
On May 20, 2026, EVGN reported earnings of -0.60 USD per share (EPS) for Q1 26, missing the estimate of -0.27 USD, resulting in a -117.86% surprise. Revenue reached 334.00 thousand, compared to an expected 357.00 thousand, with a -6.44% difference. The market reacted with a -3.24% price change (close before vs. close after earnings).
Looking ahead to Q2 26, -- analysts forecast an EPS of -0.27 USD, with revenue projected to reach 331.50 thousand USD, implying an decrease of -55.00% EPS, and decrease of -0.75% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Bionano Genomics, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.69
Actual
-$0.64
Surprise
+8.40%
Biohaven Ltd.
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.74
Actual
-$0.91
Surprise
-21.67%
Alamar Biosciences, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.33
Actual
-$0.22
Surprise
+33.83%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.55
Actual
-$0.61
Surprise
-9.83%
Enanta Pharmaceuticals, Inc
Report Date
Aug 10, 2026 For Q3 26
Estimate
-$0.52
Actual
-$0.67
Surprise
-28.80%
Rocket Pharmaceuticals, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
$0.24
Actual
-$0.15
Surprise
-160.80%
Palisade Bio, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.05
Surprise
+6.19%
DiaMedica Therapeutics Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.19
Surprise
+6.86%
Orchestra BioMed Holdings, Inc. Ordinary Shares
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.38
Surprise
+4.95%
Nkarta, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.54
Surprise
-40.81%
FAQ
What were EVOGENE LTD.'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, EVOGENE LTD. reported EPS of -$0.60, missing estimates by -117.86%, and revenue of $334.00K, -6.44% below expectations.
How did the market react to EVOGENE LTD.'s Q1 2026 earnings?
The stock price moved down -3.24%, changed from $0.74 before the earnings release to $0.72 the day after.
When is EVOGENE LTD. expected to report next?
The next earning report is scheduled for Aug 18, 2026.
What are the forecasts for EVOGENE LTD.'s next earnings report?
Based on --
analysts, EVOGENE LTD. is expected to report EPS of -$0.27 and revenue of $331.50K for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement